SANTHERA PHARMACEUTICALS
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.
SANTHERA PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2004-09-01
Address:
Liestal, Basel-Landschaft, Switzerland
Country:
Switzerland
Website Url:
http://www.santhera.com
Total Employee:
51+
Status:
Active
Contact:
41 61 906 89 50
Email Addresses:
[email protected]
Total Funding:
187.68 M USD
Technology used in webpage:
Euro Apple Whitelist
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
THC Pharm
THC Pharm develops drugs & medicinal products for the treatment of multimorbidity, cancer and neurological diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-08-17 | Juvantia Pharma | Juvantia Pharma acquired by Santhera Pharmaceuticals | N/A |
Investors List
Highbridge Capital Management
Highbridge Capital Management investment in Post-IPO Debt - Santhera Pharmaceuticals
Highbridge Capital Management
Highbridge Capital Management investment in Post-IPO Equity - Santhera Pharmaceuticals
Waypoint Capital
Waypoint Capital investment in Post-IPO Equity - Santhera Pharmaceuticals
Idorsia
Idorsia investment in Post-IPO Equity - Santhera Pharmaceuticals
Highbridge Capital Management
Highbridge Capital Management investment in Post-IPO Debt - Santhera Pharmaceuticals
YA Global Master SPV
YA Global Master SPV investment in Post-IPO Equity - Santhera Pharmaceuticals
Ares Life Sciences
Ares Life Sciences investment in Post-IPO Equity - Santhera Pharmaceuticals
Neomed Management
Neomed Management investment in Series C - Santhera Pharmaceuticals
Carnegie Asset Management
Carnegie Asset Management investment in Series C - Santhera Pharmaceuticals
The Dow Chemical Company
The Dow Chemical Company investment in Series C - Santhera Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.santhera.com
- Host name: staging.santhera.com
- IP address: 139.162.164.211
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "Santhera Pharmaceuticals"
Contact – santhera
We thank you for your interest in our company. To find information about any of the following areas or get in touch with our organization, please use the links or refer to contact information …See details»
Pharma Company - Pharmaceutical Product Manufacturing
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to developing and commercializing innovative medicines to meet the needs of patients living with rare and …See details»
santhera.com Reviews: Is this site a scam or legit?
Is santhera.com legit or a scam? Read reviews, company details, technical analysis, and more to help you decide if this site is trustworthy or fraudulent.See details»
Santhera Pharmaceuticals - Crunchbase Company …
Santhera Pharmaceuticals closed its last funding round on Jun 18, 2024 from a Post-IPO Debt round. Who are Santhera Pharmaceuticals's competitors? …See details»
Santhera Pharmaceuticals - Funding, Financials, Valuation
Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.See details»
Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular …See details»
Santhera Pharmaceuticals Ltd.
Oct 13, 2023 We are a global specialty pharmaceutical company based in Switzerland committed to development and commercialization of innovative medicines to meet the needs …See details»
Text Formatting - santhera.com
Santhera aims to market vamorolone in DMD itself in territory with population of ~ 410 million First launch in Germany in January 2024 Staged roll-out across the key European markets Strong …See details»
Santhera Implements Reorganization and Secures Financing to
Feb 11, 2020 Pratteln, Switzerland, November 2, 2020 – Santhera Pharmaceuticals (SIX: SANN) provides a corporate update following implementation of an organizational …See details»
Santhera - Pharmaceutical Company: Medicine Research
Pharmaceutical company in Switzerland committed to research & development of medicines for patients living with mitochondrial disorders & rare diseases.See details»
Santhera Pharmaceuticals (Switzerland) AG - Swiss Biotech
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and …See details»
Santhera - Overview, News & Similar companies | ZoomInfo.com
View Santhera (www.santhera.com) location in Basel-Landschaft, Switzerland , revenue, industry and description. Find related and similar companies as well as employees by title and much …See details»
Santhera Pharmaceuticals - Contacts, Employees, Board Members, …
Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.See details»
Santhera Pharmaceuticals (USA), Inc. (Santhera Pharmaceuticals …
Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix Therapeutics. For further …See details»
Santhera to share latest on commercial rollout of AGAMREE® and …
2 days ago Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix …See details»
Medicines Company - for Investors and Media - Santhera
Santhera is a company committed to developing medicines for patients with mitochondrial disorders & rare diseases. More for investors & media here!See details»
Santhera Announces Half-Year 2024 Financial Results and Provides ...
Sep 12, 2024 ommercial organization is well advanced in UK, France, Italy, Spain, and Benelux. Activities surrounding market access, stakeholder and key opinion lead r engagement in the …See details»
Santhera Announces Chief Financial Officer Transition with …
Feb 10, 2025 Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare …See details»
Santhera Announces Corporate Update and Proposal to …
Santhera will call bondholder meeting for March 8, 2021, followed by Extraordinary General Meeting in March 2021 Pratteln, Switzerland, February 16, 2021 – Santhera Pharmaceuticals …See details»
Santhera.com Reviews | Check if site is scam or legit
Mar 20, 2025 Santhera.com: Flagged as safe. Refer to our analysis, user feedback, and reports before interacting.See details»